3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

6 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-06-30

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to document the left and right ventricular function in patients with sclerodermia associated pulmonal arterial hypertension via 3D echocardiography. The results of this study should help to generate hypothesis for further future studies.

The primary hypothesis is that the increased use of modern image guided methods could provide essential aspects for the follow up.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

New Echocardiographic Methods for Right Ventricular Function.

NCT01230294

Right Ventricular Dysfunction

UNKNOWN

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

NCT06299436

Heart Failure With Reduced Ejection Fraction Pulmonary Hypertension Right Heart Failure Due to Left Heart Failure

RECRUITING

Contrast Echocardiography During Exercise to Assess Pulmonary Blood Volume

NCT06195059

Heart Failure Pulmonary Vascular Disease

RECRUITING

Enhanced Diagnosis of Ventricular Activation Pattern Using Intracardiac Electrograms

NCT02057588

Arrythmia

COMPLETED NA

3D Echocardiographic Assessment of RV Function in Patients Undergoing Pulmonary Endarterectomy

NCT02426203

Chronic Thromboembolic Pulmonary Hypertension

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The 3D echocardiography could provide early and detailed information about the changes in the left and right ventricle.

The prediction of sclerodermia associated pulmonary arterial hypertension (PAH) is rather adverse, so it makes sense to evaluate relevant changes of the left-ventricular longitudinal strain soon to adapt the PAH specific therapy accordingly.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

no treatment

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \>17
* pulmonary arterial hypertension (PAH) associated with WHO group 1 who start a parenteral prostanoid-therapy
* written informed consent
* prostanoid naive
* no change of the PAH specific therapy within 3 weeks of the recruitment to the study

Exclusion Criteria

* pregnancy and lactation period
* Women of child bearing potential who do not use an effective and secure method for birth control
* severe chronic kidney insufficiency (glomerular filtration rate \<30), which will remain for more than 3 months
* liver-insufficiency Child C
* life expectancy shorter than the course of the study (for example because of malignant disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No